Please ensure Javascript is enabled for purposes of website accessibility

Can These Top-Performing Biotech Stocks Keep Climbing?

By Cory Renauer – Apr 30, 2018 at 3:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the past year, these two biotech stocks outperformed nearly all their peers. Can they keep it going?

A year ago few of us had ever heard of CASI Pharmaceuticals Inc. (CASI 6.64%), and Mirati Therapeutics Inc. (MRTX 4.37%). Over the past twelve months, though, they've delivered returns that their lucky shareholders won't ever forget.

Let's peek into the operations propelling these stocks skyward to see if they can keep climbing.

CASI Chart

CASI data by YCharts.

CASI Pharmaceuticals: East-west pharma merchant?

CASI Pharmaceuticals is a decades-old U.S. biotech without any revenue that intends to market cancer therapies it licensed from Spectrum Pharmaceuticals (SPPI 8.49%) in an enormous market clamoring for such medicines -- China. The stock shot up 84% in September after the company announced China's Food and Drug Administration (CFDA) granted one of those therapies, Evomela, a priority review.

The stock soared again earlier this month after the company announced the CFDA would convene a panel of independent experts to discuss its application. The scheduled date has since passed, but so far we haven't heard a word from the closed meeting.

Evomela is essentially a new formulation of an old therapy for multiple myeloma that the U.S Food and Drug Administration approved in 2016. It only generated $35.2 million in sales for Spectrum in 2017, but there's a chance it could really take off in China, where patients still can't access the old version or a slew of other treatments.

Around two-thirds of new drugs approved by the U.S. FDA between 2001 and 2016 still aren't available in China, largely because the CFDA rarely accepts data generated outside its own borders. Some countries insist that pharma companies run late-stage studies within their own borders, but foreign drugmakers often need to repeat the development process beginning at preclinical stages to meet stifling Chinese regulations.

The CFDA is making some dramatic changes to the way it regulates foreign-sponsored applications, and that could lead to a flood of competition for Evomela. In February, the regulator approved Celgene's (CELG) Revlimid for the treatment of newly diagnosed multiple myeloma patients, based on results that showed it outperformed a regimen that contains Evomela's active ingredient.

A recent collaboration deal means Beijing's BeiGene will market Celgene's therapies on domestic turf. With this in mind, I wouldn't look for further gains from CASI Pharmaceuticals until the company starts booking significant sales.

Three scientists looking at a test tube

Image source: Getty Images.

Mirati Therapeutics: The next Nektar?

Checkpoint inhibitor drugs -- which take the brakes off the immune system so they can attack tumors -- produce tremendous results, but only for some patients. Earlier this year, Bristol-Myers Squibb (BMY 2.42%) announced a $3.6 billion deal with Nektar Therapeutics (NKTR 5.25%) for limited rights to a candidate that looks like it can boost the addressable patient population for its checkpoint inhibitor Opdivo.

Mirati Therapeutics stock started soaring in September after Mirati released data that suggests a big collaboration deal could be in its future as well. Three of 11 evaluable lung cancer patients who had already progressed following treatment with a checkpoint inhibitor showed responses to a combination of Opdivo and Mirati's lead candidate, sitravatinib. More recently, the number of partial responses rose to six out of the first 23 evaluable patients receiving the combination treatment.

A 26% response rate among patients who had already relapsed after treatment with a drug like Opdivo might entice Bristol-Myers Squibb to make a Mirati a Nektar-sized offer down the road. Unfortunately, we don't have comparison data to prove that adding sitravatinib to Opdivo is what caused the tumors to shrink. If we've learned anything recently, it's that single-arm combination studies with checkpoint inhibitors can be misleading.

Consider the odds

Without data from a controlled study, it's hard to imagine Bristol-Myers offering Mirati anything beyond access to more Opdivo. The company is running several single-arm studies but hasn't started anything with a control group yet. At recent prices Mirati sports a big $904 million market cap that probably won't get much bigger unless it signs a deal with Bristol-Myers or one of its peers.

It's going to be a long time before Mirati can generate the sort of data that might lead to a meaningful partnership, and an unlucky result in the meantime could lead to swift and heavy losses. That makes CASI the more likely of the two to continue climbing.

With a recent market cap around $576 million, CASI could slide backward if Spectrum's drugs flop in China. That said, at least we can reasonably expect it to bring in some product revenue in the quarters ahead.

Cory Renauer owns shares of, and The Motley Fool owns shares of and recommends, Celgene. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mirati Therapeutics, Inc. Stock Quote
Mirati Therapeutics, Inc.
$70.51 (4.37%) $2.95
CASI Pharmaceuticals, Inc. Stock Quote
CASI Pharmaceuticals, Inc.
$2.89 (6.64%) $0.18
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$72.06 (2.42%) $1.70
Spectrum Pharmaceuticals, Inc. Stock Quote
Spectrum Pharmaceuticals, Inc.
$0.48 (8.49%) $0.04
Celgene Corporation Stock Quote
Celgene Corporation
Nektar Therapeutics Stock Quote
Nektar Therapeutics
$3.21 (5.25%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.